Human Faecal Microbiota in Type 2 Diabetes
perjantai 26. helmikuuta 2016 päivittänyt: Société des Produits Nestlé (SPN)
Analysis of the Diversity of Faecal Bacteria in Healthy and Type 2 Diabetic Subjects
The main objective of the clinical trial is to investigate whether overweight type 2 diabetic patients have a different fecal microbiota profile compared with age, gender, BMI matched subjects and with lean healthy subjects before and after the consumption of fiber rich cereal bars.
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Yksityiskohtainen kuvaus
Gut microbiota refers to the bacterial communities in the gastrointestinal tract.
The diversity and quantity of bacteria vary depending on age of the individuals, daily diet and the segment of the intestine, which makes the gut microbiota one of the most complex bacterial ecosystems known to men.
In general, over trillions of bacteria reside in human gut.
Recent evidence indicates that gut microbiota could be involved in host metabolism by multiple pathways leading to the development of obesity and type 2 diabetes.
Increased fat storage or obesity has become one of the leading public health issues in many developed and developing countries.
However, it is not clear whether type 2 diabetes is associated with a unique gut microbiota profile.
Therefore, the primary objective of the study is to compare the fecal microbiota of overweight type 2 diabetic subjects to that of age, gender and BMI matched subjects as well as with lean non-diabetic subjects.
In addition, the investigators hypothesize that microbiota modifications with consumption of fiber rich food products can improve the metabolic outcomes of type 2 diabetics.
To test this hypothesis, the investigators plan to provide each overweight participant with two cereal bars per day for 4 weeks.
Anthropometric measurements and plasma parameters as well as the fecal microbiota will be determined.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
67
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
30 vuotta - 55 vuotta (Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
-All diabetic and control non-diabetic subjects (of same BMI) must comply with all the following inclusion criteria:
- Ethnic background: Caucasian
- BMI: 25 to 40 kg/m2
- Fasting blood glucose > 7 mmol/L
- Fasting Hemoglobin A1c > 7%
- Consume mainly typical Western diets daily
- Having obtained his/her informed consent
Lean non-diabetic healthy subjects must comply with the following inclusion criteria:
- Ethnic background: Caucasian
- BMI: 20 to 25 kg/m2
- Fasting blood glucose < 5.5 mmol/L
- Fasting Hemoglobin A1c < 6 %
- Consume mainly typical Western diets daily
- Having obtained his/her informed consent
Exclusion Criteria:
Diabetic and healthy (same BMI) subjects representing one or more of the following criteria are excluded from participation in the study.
- Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
- People actively take cortisol or dexamethasone should be excluded from the study
- People under a-amylase/a-glucosidase inhibitors should be excluded from the study. However, patients under metformin can be accepted for this study.
- Patients under metformin suffering from gastrointestinal side effects within a 6-month time period prior to the trial
- Regular consumption of fermented dairy products
- Vegetarians
- Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
- HIV seropositive
- Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
- Patients who cannot be expected to comply with treatment
- Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
- Females with hormone therapy will be excluded from the study
Lean healthy subjects representing one or more of the following criteria are excluded from participation in the study.
- Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
- Regular consumption of fermented dairy products
- Vegetarians
- Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
- HIV seropositive
- Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
- Patients who cannot be expected to comply with treatment
- Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
- Females with hormone therapy will be excluded from the study
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Ei väliintuloa: Lean non diabetic
Lean and healthy subjects receiving no intervention
|
|
|
Kokeellinen: Overweight non diabetic
fiber rich cereal bars, two bars a day for 4 weeks
|
Two cereals per day and per subject for 4 weeks
Muut nimet:
|
|
Kokeellinen: Overweight diabetic
fiber rich cereal bars, two bars a day for 4 weeks
|
Two cereals per day and per subject for 4 weeks
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Fecal microbiota profile
Aikaikkuna: Baseline samples taken after 2 weeks of diet normalization period
|
Fecal samples taken after the two week diet normalization are subjected to bacteria 16S rDNA sequencing and by quantitative PCR.
|
Baseline samples taken after 2 weeks of diet normalization period
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Metabonomic analysis in faeces
Aikaikkuna: Samples taken after 2 weeks of diet normalization period (baseline) and 4 weeks of cereal bars intake when applicable
|
Samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period (baseline) and 4 weeks of cereal bars intake when applicable
|
|
Metabonomic analysis in plasma
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Metabonomic analysis in urine
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
Then, samples are analyzed by 1HNMR.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma glucose
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma insulin
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma free fatty acids
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma triglycerides
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma total cholesterol
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
|
Plasma HDL cholesterol
Aikaikkuna: Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Baseline samples for lean non-diabetic, overweight non-diabetic and overweight diabetic subjects.
Post intervention samples from overweight non-diabetic and diabetic subjects.
|
Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Alain Golay, Prof, University Hospital, Geneva
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Lauantai 1. syyskuuta 2007
Ensisijainen valmistuminen (Todellinen)
Maanantai 1. kesäkuuta 2009
Opintojen valmistuminen (Todellinen)
Perjantai 1. huhtikuuta 2011
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 18. helmikuuta 2016
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Perjantai 26. helmikuuta 2016
Ensimmäinen Lähetetty (Arvio)
Maanantai 29. helmikuuta 2016
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Maanantai 29. helmikuuta 2016
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 26. helmikuuta 2016
Viimeksi vahvistettu
Maanantai 1. helmikuuta 2016
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 06.42.NRC
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .